Thrilling AIDS activists and frustrating the drug company, an Indian court rejected Novartis' challenge to its drug patent laws [1]. Novartis claims the decision will discourage innovation. Indian law doesn't allow new patents on drugs that have simply been modified, rather than newly developed. That throws a big wrench into drug makers' strategy for combating cheaper generics: namely, using a few pips and tweaks to turn old, once-profitable meds into new, patent-protected ones. The ruling will help protect India's burgeoning generics industry from Big Pharma competition and, say patient advocates, keeps inexpensive remedies coming to populations that couldn't afford them otherwise.

- here's the report [2] from the International Herald Tribune

Related Articles:
Novartis patent challenge spurs protests in India. Report [3]
Generic competition slashes prices. Report [4]
India's biotech future is bright. Report [5]